Merging Innovation, Translational Medicine, and Entrepreneurship in Biomedical En

融合生物医学领域的创新、转化医学和创业精神

• 批准号: 8726984
• 负责人: Martin L Yarmush
• 金额: $ 4.32万
• 依托单位: RUTGERS, THE STATE UNIV OF N.J.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8726984
• 关键词: Accounting; Address; Affect; Biomedical Engineering; Businesses; Case Study; Clinical; Device Designs; Device or Instrument Development; Discipline; Economics; Educational Curriculum; Educational process of instructing; Emerging Technologies; Engineering; Entrepreneurship; Faculty; Familiarity; Goals; Health; Healthcare Industry; Immersion Investigative Technique; Industry; Instruction; Learning; Legal; Marketing; Medical; Mentors; Participant; Patient Care; Patients; Personal Communication; Physicians; Process; Running; Sales; Schools; Solutions; Students; Translations; Universities; Wood material; Work; base; career; clinically significant; commercialization; cost; design; experience; falls; innovation; instructor; lectures; medical schools; operation; programs; skills; translational medicine

DESCRIPTION (provided by applicant): Our proposal aims at redefining the essence of team-based Senior Design projects in Biomedical Engineering and is based on the realization that in addition to the basic technical, communication and interpersonal skills acquired in a typical 4-year engineering curriculum, successful careers in the health industry require an understanding of how a business functions (marketing and sales, accounting and finance, and operations) and familiarity with the legal, regulatory, and economic constraints affecting patient care device design and development. While Biomedical Engineers need not become experts in all the above, it is critical for them to understand and appreciate these issues. The goal of this proposal is to implement a new Senior Design experience for BME students focused on the integration of biomedical engineering and clinical disciplines with translation of innovation to industry. There are three specific aims: Aim 1: To incorporate basic aspects of translational medicine and innovation commercialization into the lecture component of the Senior Design course. The lecture component, which is primarily given in the fall semester of the senior year, will be overhauled to include lectures given by instructors from the medical and business schools. Aim 2: To increase the clinical significance of Senior Design projects offered to BME seniors. Students will be able to apply for a clinical immersion program in the summer prior to their senior year and will be encouraged to identify needs that can be addressed through biomedical engineering solutions. Medical and Business School faculty, as well as industrial advisors will be invited to develop and mentor senior design projects. Aim 3: To provide a path for translation and commercialization for the most successful senior design projects. A selection process will be implemented whereby about 20% of the projects will be selected at the end of the fall semester for matching with an entrepreneurship course where they become case studies for marketing and financial analysis. At the end of the spring, one or two projects will be further evaluated and pushed towards actual commercialization. The program participants will be the entire senior class of BME students at Rutgers, and the program will be run through the collaborative efforts of the Rutgers Center for Innovative Ventures of Emerging Technology, the Department of Biomedical Engineering at Rutgers, the Robert Wood Johnson School of Medicine, and the Rutgers Business School. Students will tremendously benefit from the proposed upgrade to the Senior Design course because they will be working on projects that are better tailored towards the needs of patients and physicians. They will also get a better understanding of the down-to-earth practical - yet critical - non-technical issues that must be considered when designing new products, such as the competition, market acceptance, cost, and other related considerations.

描述（申请人提供）：我们的建议旨在重新定义生物医学工程中基于团队的高级设计项目的本质，并基于这样的认识，即除了在典型的4年工程课程中获得的基本技术，沟通和人际交往技能外，健康行业的成功职业需要了解企业如何运作（营销和销售、会计和财务以及运营），熟悉影响患者护理器械设计和开发的法律的、法规和经济限制。虽然生物医学工程师不需要成为上述所有方面的专家，但他们理解和理解这些问题至关重要。这项提案的目的是 为BME学生提供新的高级设计体验，专注于生物医学工程和临床学科的整合，并将创新转化为行业。有三个具体目标：目标1：将转化医学和创新商业化的基本方面纳入高级设计课程的讲座部分。讲座部分，这主要是在高年级的秋季学期给出，将进行彻底改革，包括从医学院和商学院的讲师给出的讲座。目的2：增加为BME老年人提供的高级设计项目的临床意义。学生将能够在大四之前的夏天申请临床沉浸式课程，并将被鼓励确定可以通过生物医学工程解决方案解决的需求。医学院和商学院的教师，以及工业顾问将被邀请开发和指导高级设计项目。目标3：为最成功的高级设计项目提供翻译和商业化的途径。将实施一个选择过程，其中约20%的项目将在秋季学期结束时被选中，与创业课程相匹配，在那里它们将成为营销和财务分析的案例研究。在春季结束时，将对一两个项目进行进一步评估，并推动其走向实际商业化。该计划的参与者将是整个高年级班的BME学生在罗格斯大学，该计划将通过罗格斯大学新兴技术创新创业中心，罗格斯大学生物医学工程系，罗伯特伍德约翰逊医学院和罗格斯商学院的合作努力。学生将极大地受益于拟议的升级到高级设计课程，因为他们将致力于更好地适应患者和医生的需求的项目。他们还将更好地了解设计新产品时必须考虑的实际但关键的非技术问题，例如竞争，市场接受度，成本和其他相关考虑因素。